Wardwizard Healthcare Limited has announced a significant change in its key management personnel. The company disclosed that Mr. Dikshant Singh Panwar has stepped down from his position as Company Secretary and Compliance Officer, effective October 16, 2025.

Resignation Details

Mr. Panwar, who holds the membership number A42741, tendered his resignation citing personal reasons. His departure will be effective from the closure of business hours on October 16, 2025. Wardwizard Healthcare made this announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Information

Company's Response

In the official communication, it was noted that Mr. Panwar expressed his gratitude to each member of the board for their valuable guidance and contribution during his tenure. The Board, in turn, wished him continued success and the very best for all his future endeavors.

Wardwizard Healthcare has not yet announced a replacement for the position of Company Secretary and Compliance Officer. As per regulatory requirements, the company will need to fill this crucial role to ensure continued compliance with corporate governance norms.

This change in key managerial personnel comes at a time when companies are increasingly focusing on strong corporate governance practices. The role of Company Secretary and Compliance Officer is vital in ensuring that a company adheres to regulatory requirements and maintains transparency in its operations.

Investors and stakeholders will be keen to see how Wardwizard Healthcare manages this transition and who may be appointed to this critical position in the future.

Wardwizard Healthcare Limited , formerly known as Ayoki Mercantile Limited, has announced the approval of its unaudited standalone financial results for the first quarter of the fiscal year 2025-26. The company's Board of Directors convened on August 11, 2025, to review and approve the financial statements for the quarter ended June 30, 2025.

Key Highlights

• The Board meeting commenced at 11:30 AM IST and concluded at 2:40 PM IST on August 11, 2025.
• The Audit Committee recommended the financial results before the Board's approval.
• Statutory auditors M/S. Mahesh Udhwani & Associates, Chartered Accountants, provided a Limited Review Report on the financial statements.

Financial Results Submission

The company has submitted its unaudited financial results to the BSE Limited in compliance with Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The submission includes:

1. A copy of the Limited Review Reports issued by the Statutory Auditors on the financial results.
2. A copy of the Un-audited Financial Results (Standalone) for the first quarter and three months ended June 30, 2025.

Transparency and Compliance

Wardwizard Healthcare Limited has ensured transparency by making the financial results available on the company's website at www.ayokimerchantile.com . This move allows investors and stakeholders easy access to the company's financial performance for the quarter.

Management Commentary

While specific financial figures were not disclosed in the available information, the company's management has fulfilled its regulatory obligations by timely reporting of the quarterly results. The approval and submission of these results demonstrate Wardwizard Healthcare Limited's commitment to maintaining good corporate governance practices and keeping its shareholders informed.

About Wardwizard Healthcare Limited

Wardwizard Healthcare Limited, formerly known as Ayoki Mercantile Limited, recently underwent a name change which may reflect a shift in its business focus or strategy. However, specific details about its operations were not provided in the current disclosure.

Investors and interested parties are encouraged to refer to the detailed financial results available on the company's website and the BSE portal for a comprehensive understanding of Wardwizard Healthcare Limited's financial performance in the first quarter of FY2025-26.